White matter damage, neuroinflammation, and neuronal integrity in HAND.


Journal

Journal of neurovirology
ISSN: 1538-2443
Titre abrégé: J Neurovirol
Pays: United States
ID NLM: 9508123

Informations de publication

Date de publication:
02 2019
Historique:
received: 21 08 2018
accepted: 24 09 2018
pubmed: 7 10 2018
medline: 8 9 2020
entrez: 7 10 2018
Statut: ppublish

Résumé

HIV-associated neurocognitive disorders (HANDs) persist even with virologic suppression on combination antiretroviral therapy (cART), and the underlying pathophysiological mechanisms are not well understood. We performed structural magnetic resonance imaging and MR spectroscopy (MRS) in HIV+ individuals without major neurocognitive comorbidities. Study participants were classified as neurocognitively unimpaired (NU), asymptomatic (ANI), mild neurocognitive disorder (MND), or HIV-associated dementia (HAD). Using structural MRI, we measured volumes of cortical and subcortical gray matter and total and abnormal white matter (aWM). Using single-voxel MRS, we estimated metabolites in frontal gray matter (FGM) and frontal white matter (FWM) and basal ganglia (BG) regions. Adjusted odds ratios were used to compare HAND to NU. Among 253 participants, 40% met HAND criteria (21% ANI, 15% MND, and 4% HAD). Higher risk of HAND was associated with more aWM. Both HAD and MND also had smaller gray and white matter volumes than NU. Among individuals with undetectable plasma HIV RNA, structural volumetric findings were similar to the overall sample. MND had lower FWM creatine and higher FGM choline relative to NU, whereas HAD and ANI had lower BG N-acetyl aspartate relative to NU. In the virologically suppressed subgroup, however, ANI and MND had higher FGM choline compared to NU. Overall, HAND showed specific alterations (more aWM and inflammation; less gray matter volume and lower NAA). Some MR measures differentiated less severe subtypes of HAND from HAD. These MR alterations may represent legacy effects or accumulating changes, possibly related to medical comorbidities, antiretroviral therapy, or chronic effects of HIV brain infection.

Identifiants

pubmed: 30291567
doi: 10.1007/s13365-018-0682-9
pii: 10.1007/s13365-018-0682-9
pmc: PMC6416232
mid: NIHMS998482
doi:

Substances chimiques

Anti-HIV Agents 0
Aspartic Acid 30KYC7MIAI
N-acetylaspartate 997-55-7
Creatine MU72812GK0
Choline N91BDP6H0X

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

32-41

Subventions

Organisme : NICHD NIH HHS
ID : R21 HD094646
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA031098
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH062512
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI036214
Pays : United States
Organisme : Foundation for the National Institutes of Health
ID : [N01 MH2205 and HHSN271201000036C
Pays : International
Organisme : NIMH NIH HHS
ID : R01 MH107345
Pays : United States
Organisme : Foundation for the National Institutes of Health
ID : P30 MH62512
Pays : International
Organisme : NIMH NIH HHS
ID : U24 MH100930
Pays : United States

Références

Neurol Neuroimmunol Neuroinflamm. 2018 Jan 03;5(1):e430
pubmed: 29312999
Neurology. 2016 Jan 26;86(4):334-40
pubmed: 26718568
J Neurovirol. 2013 Aug;19(4):393-401
pubmed: 23838849
AIDS. 2016 Sep 24;30(15):2329-39
pubmed: 27149087
Curr HIV/AIDS Rep. 2010 May;7(2):69-76
pubmed: 20425560
Neuroimage. 2007 Apr 1;35(2):478-87
pubmed: 17292629
Radiology. 2006 Aug;240(2):318-32
pubmed: 16864664
AIDS. 2007 Sep 12;21(14):1915-21
pubmed: 17721099
J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):469-77
pubmed: 22269799
J Med Phys. 2010 Jul;35(3):154-63
pubmed: 20927223
Arch Neurol. 1997 Apr;54(4):416-24
pubmed: 9109743
Semin Neurol. 2014 Feb;34(1):89-102
pubmed: 24715492
J Neurovirol. 2015 Oct;21(5):559-67
pubmed: 26069183
Neurology. 2002 Dec 24;59(12):1944-50
pubmed: 12499488
Arch Neurol. 2004 Mar;61(3):369-76
pubmed: 15023814
J Int Neuropsychol Soc. 2008 Sep;14(5):725-33
pubmed: 18764968
J Int Neuropsychol Soc. 2004 May;10(3):317-31
pubmed: 15147590
Magn Reson Imaging. 2010 Nov;28(9):1251-7
pubmed: 20688449
Neurology. 2007 Oct 30;69(18):1789-99
pubmed: 17914061
Brain Imaging Behav. 2011 Jun;5(2):77-85
pubmed: 21264551
NMR Biomed. 2001 Jun;14(4):260-4
pubmed: 11410943
AJR Am J Roentgenol. 1987 Aug;149(2):351-6
pubmed: 3496763
J Neurovirol. 2009 Jul;15(4):324-33
pubmed: 19499454
Rehabil Psychol. 2011 Feb;56(1):77-84
pubmed: 21401289
Neuroimage. 2004 Dec;23(4):1336-47
pubmed: 15589098
J Neurovirol. 2013 Jun;19(3):209-18
pubmed: 23613008
Lancet Infect Dis. 2013 Nov;13(11):976-86
pubmed: 24156898
Clin Geriatr Med. 2007 Aug;23(3):567-83, vii
pubmed: 17631234
J Neurovirol. 2017 Jun;23(3):422-429
pubmed: 28101804
J Neurovirol. 2011 Jun;17(3):248-57
pubmed: 21544705
J Neurovirol. 2012 Aug;18(4):291-302
pubmed: 22653528
J Neurovirol. 2014 Feb;20(1):39-53
pubmed: 24420448
Prog Neurobiol. 2017 Oct;157:117-132
pubmed: 27084354
AIDS. 2011 Mar 13;25(5):625-33
pubmed: 21297425
Neurology. 2010 Dec 7;75(23):2087-96
pubmed: 21135382
Clin Infect Dis. 2017 Apr 15;64(8):1059-1065
pubmed: 28329096
Neuroimage. 2004 Nov;23(3):928-35
pubmed: 15528093
J Neurovirol. 2017 Aug;23(4):539-547
pubmed: 28324319
J Neurovirol. 2014 Dec;20(6):603-11
pubmed: 25227933

Auteurs

Aljoharah Alakkas (A)

University of California at San Diego, La Jolla, CA, USA. alalakka@ad.ucsd.edu.

Ronald J Ellis (RJ)

University of California at San Diego, La Jolla, CA, USA.

Caitlin Wei-Ming Watson (CW)

University of California at San Diego, La Jolla, CA, USA.

Anya Umlauf (A)

University of California at San Diego, La Jolla, CA, USA.

Robert K Heaton (RK)

University of California at San Diego, La Jolla, CA, USA.

Scott Letendre (S)

University of California at San Diego, La Jolla, CA, USA.

Ann Collier (A)

University of Washington, Seattle, WA, USA.

Christina Marra (C)

University of Washington, Seattle, WA, USA.

David B Clifford (DB)

Washington University School of Medicine, St. Louis, MO, USA.

Benjamin Gelman (B)

University of Texas Medical Branch, Galveston, TX, USA.

Ned Sacktor (N)

The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Susan Morgello (S)

The Mount Sinai Hospital, New York, NY, USA.

David Simpson (D)

The Mount Sinai Hospital, New York, NY, USA.

J Allen McCutchan (JA)

University of California at San Diego, La Jolla, CA, USA.

Asha Kallianpur (A)

Cleveland Clinic and Lerner Research Institute, Cleveland, OH, USA.

Sara Gianella (S)

University of California at San Diego, La Jolla, CA, USA.

Thomas Marcotte (T)

University of California at San Diego, La Jolla, CA, USA.

Igor Grant (I)

University of California at San Diego, La Jolla, CA, USA.

Christine Fennema-Notestine (C)

University of California at San Diego, La Jolla, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH